Marker Therapeutics (MRKR) Other financing activities (2010 - 2024)
Marker Therapeutics (MRKR) posted quarterly Other financing activities of $3658.0 for Q4 2024, down 28.76% year-over-year from $5135.0 in Q1 2024, and up 115.05% quarter-over-quarter from $1701.0 in Q3 2024.
Marker Therapeutics (MRKR) Other financing activities (2010 - 2024) Analysis & Trends
Marker Therapeutics (MRKR) has reported Other financing activities for 12 consecutive years, with $3658.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Other financing activities fell 28.76% year-over-year to $3658.0; the TTM figure through Dec 2024 stood at $62159.0 (down 30.74% YoY), while the FY2024 annual figure was $62159.0, down 31.3% from the prior year.
- Other financing activities climbed to $3658.0 in Q4 2024 per MRKR's latest filing, from $1701.0 in the prior quarter.
- Across five years, Other financing activities topped out at $550000.0 in Q1 2020 and bottomed at $1701.0 in Q3 2024.
- Historically, Other financing activities has averaged $88123.4 across 4 years, with a median of $6419.5 in 2023.
- Annual changes were most pronounced in 2020 — Other financing activities soared 10124.95% — and 2024, when it slumped 97.99%.
- Marker Therapeutics' Other financing activities stood at $550000.0 in 2020, then slumped by 99.44% to $3087.0 in 2021, then jumped by 66.34% to $5135.0 in 2023, then dropped by 28.76% to $3658.0 in 2024.
- Business Quant data shows MRKR's Other financing activities at $3658.0 in Q4 2024, $1701.0 in Q3 2024, and $7704.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3,658.00 |
| Dec 31, 2024 | 3,658.00 |
| Sep 30, 2024 | 1,701.00 |
| Sep 30, 2024 | 1,701.00 |
| Jun 30, 2024 | 7,704.00 |
| Jun 30, 2024 | 7,704.00 |
| Mar 31, 2024 | 49,096.00 |
| Mar 31, 2024 | 49,096.00 |
| Dec 31, 2023 | 5,135.00 |
| Dec 31, 2023 | 5,135.00 |
| Sep 30, 2023 | 84,606.00 |
| Sep 30, 2023 | 84,606.00 |
| Jun 30, 2021 | 3,087.00 |
| Jun 30, 2021 | 3,087.00 |
| Mar 31, 2020 | 550,000.00 |
| Mar 31, 2020 | 550,000.00 |
| Sep 30, 2019 | 52,365.00 |
| Sep 30, 2019 | 52,365.00 |
| Mar 31, 2019 | 5,379.00 |
| Mar 31, 2019 | 5,379.00 |